This suggests that even a low level of expression of TRAIL-R2 (for example in Me64) may be sufficient to induce the immunological synapse (bridging CD3 and TRAIL-R2 through the bsAb) needed for T cell activation and subsequent anti-tumor functions in lymphocyte-tumor co-cultures where the bsAb is added. This evidence concerns the gene TNFRSF10B and neoplasm.